Effects of Saxagliptin combined with Glimepiride in treatment of type 2 diabetes mellitus complicated with obesity
Objective:To observe effects of Saxagliptin combined with Glimepiride in treatment of type 2 diabetes mellitus with obesity. Methods:The clinical data of 60 patients with type 2 diabetes mellitus complicated with obesity admitted to this hospital from 2021 to 2022 were retrospectively analyzed. According to different treatment methods,they were divided into control group and observation group,30 cases in each group. Both groups were given basic treatment and diet and exercise guidance. On this basis,the control group was treated with Glimepiride,while the observation group was treated with Saxagliptin on the basis of that of the control group. Both groups were treated continuously for 3 months. The clinical efficacy,the levels of blood glucose indexes[fasting blood glucose (FPG),2 h postprandial blood glucose (2hPG),glycosylated hemoglobin (HbA1c)],islet function indexes[fasting insulin (FINS),insulin resistance index (HOMA-IR),islet β cell function index (HOMA-β)]and body mass index (BMI) before and after the treatment,and the incidence of adverse reactions were compared between the two groups. Results:The total effective rate of the observation group was 96.67％ (29/30),which was higher than 73.33％ (22/30) of the control group,and the difference was statistically significant (P<0.05). After the treatment,the levels of FPG,2hPG,HbA1c,FINS and HOMA-IR in the observation group were lower than those in the control group,the level of HOMA-β was higher than that in the control group,and the differences were statistically significant (P<0.05). After the treatment,the BMI level of the observation group was lower than that of the control group,and the difference was statistically significant (P<0.05). However,there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions:Saxagliptin combined with Glimepiride in the treatment of type 2 diabetes mellitus with obesity can improve the total effective rate of treatment,improve the levels of blood glucose indexes and islet function indexes,and reduce the BMI levels. Moreover,it is superior to simple Glimepiride treatment.
Type 2 diabetesObesitySaxagliptinGlimepirideBlood glucoseIslet functionBody mass index
万方数据
维普
